期刊文献+

利伐沙班在心血管疾病中应用的临床进展 被引量:4

Clinical Progress of Rivaroxaban in Cardiovascular Diseases
下载PDF
导出
摘要 利伐沙班与传统抗凝药物疗效相似,无需常规监测凝血功能,与药物和食物的相互作用较少,出血风险小。目前已被广泛用于骨科术后预防静脉血栓形成、深静脉血栓以及肺动脉栓塞、非瓣膜性心房颤动、急性冠脉综合征、外周动脉病等多种血栓栓塞性疾病的治疗及预防。 Rivaroxaban has a similar efficacy to traditional anticoagulants and does not require monitoring coagulation indicators.Furthermore,it has little affected by drugs and food,and has little bleeding risk.At present,rivaroxaban has been widely used in prevention of venous thrombosis after orthopedic surgery and treatment of deep venous thrombosis,pulmonary embolism,nonvalvular atrial fibrillation,acute coronary syndrome,peripheral arterial disease and so on.
作者 林莹 徐勇 郭新红 刘昱圻 LIN Ying;XU Yong;GUO Xinhong;LIU Yuqi(Department of Cardiology,Chinese PLA General Hospital,Beijing 100853,China;Department of Cardiology,Hainan Hospital of Chinese PLA General Hospital,Sanya 572013,Hainan,China)
出处 《心血管病学进展》 CAS 2020年第3期247-250,共4页 Advances in Cardiovascular Diseases
关键词 利伐沙班 抗凝 心血管疾病 有效性 安全性 Rivaroxaban Anticoagulation Cardiovascular diseases Efficacy Safety
  • 相关文献

参考文献5

二级参考文献78

  • 1李小鹰,王洁,何耀,范利.老年周围动脉硬化闭塞病与心血管疾病的关系——北京万寿路地区老年人群横断面调查[J].中华医学杂志,2003,83(21):1847-1851. 被引量:36
  • 2李立明,饶克勤,孔灵芝,姚崇华,向红丁,翟凤英,马冠生,杨晓光,中国居民营养与健康状况调查技术执行组.中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484. 被引量:1783
  • 3Pinto DJ ,Qiao JX ,Knabb RM. The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases :a patent review[J]. Expert Opin Ther Pat,2012,22(6) :645-661.
  • 4Kubitza D, Becka M, Wensing G, et al. Safety,pharmacodynamics ,and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects[J]. Eur J Clin Pharmacol,2005, 61 (12) : 873-880.
  • 5Gulseth MP, Michaud J, Nutescu EA, et al. Rivaroxaban : an oral direct inhibitor of factor Xa [J]. Am J Health Syst Pharm, 2008,65 (16) : 1520 - 1529.
  • 6Perzbom E, Strassburger J,Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa in- hibitor[J]. J Thromb Haemost ,2005,3(3) :514-521.
  • 7Kubitza D, Becka M, Wensing G, et al. Safety,pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects[J]. Clin J Phar- macol, 2005,61 ( 12 ) : 873-880.
  • 8Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of throm- bin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban[J]. J Thromb Haemost, 2007,5 (4) :886- 888.
  • 9Ansell J ,Hirsh J,Poller L,et al. The pharmacology and management of the vitamin Kantagonists :the Seventh ACCP Conference on Antithrombotie and Thrombolytie Therapy[J]. Chest, 2004,126 (3S) : 204S-233S.
  • 10Turpie AG, Lassen MR, Davidson BL,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORIM) :a ran- domised tral[J]. Lancet, 2009,373 (9676) : 1673-1680.

共引文献1251

同被引文献62

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部